FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to PD-L1 binding peptides, and can be used to obtain PD-L1 protein antagonist, for detection or for clinical analysis of PD-L1 protein expression.
EFFECT: invention provides a peptide capable of binding to human PD-L1, with high affinity.
7 cl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| HUMANIZED ANTIBODY AGAINST PD-1 AND ITS USE | 2019 |
|
RU2803460C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2776121C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2744959C2 |
| NOVEL ANTI-PD-L1 ANTIBODIES | 2016 |
|
RU2736151C2 |
| NOVEL ANTI-PD-1 ANTIBODIES | 2016 |
|
RU2729830C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
